Chronic treatment with taurine ameliorates diabetes-induced dysfunction of nitric oxide-mediated neurogenic and endothelium-dependent corpus cavernosum relaxation in rats

Fundamental and Clinical Pharmacology

Volumn 28, Issue 4, 2014, Pages 394-404

  Dalaklioglu, Selvinaz ^a   Kuscu, Nilay ^a   Celik Ozenci, Ciler ^a   Bayram, Zeliha ^a   Nacitarhan, Cahit ^a   Ozdem, Sadi Satilmis ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Corpus cavernosum; Diabetes mellitus; NADPH oxidase; Nitric oxide; Rho kinase; Taurine

Indexed keywords

ACETYLCHOLINE; APAMIN; CHARYBDOTOXIN; DRINKING WATER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SILDENAFIL; STREPTOZOCIN; TAURINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG EFFICACY; ELECTRIC FIELD; ELECTROSTIMULATION; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; VASODILATATION; ANIMAL; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PENIS; VASCULAR ENDOTHELIUM; WISTAR RAT;

ACETYLCHOLINE; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ENDOTHELIUM, VASCULAR; MALE; NADPH OXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE I; NITRIC OXIDE SYNTHASE TYPE III; PENIS; RATS; RATS, WISTAR; RHO-ASSOCIATED KINASES; STREPTOZOCIN; TAURINE;

EID: 84904042745     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12041     Document Type: Article

References (48)

1. Vickers M.A., Wright E.A. Erectile dysfunction in the patient with diabetes mellitus. Am. J. Manag. Care (2004) 10 S3-S11.
2. Gandaglia G., Salonia A., Passoni N., Montorsi P., Briganti A., Montorsi F. Erectile dysfunction as a cardiovascular risk factor in patients with diabetes. Endocrine (2013) 43 285-292.
3. Yamada T., Hara K., Umematsu H., Suzuki R., Kadowaki T. Erectile dysfunction and cardiovascular events in diabetic men: a meta-analysis of observational studies. PLoS One (2012) 7 e43673.
4. Keegan A., Cotter M.A., Cameron N.E. Effects of diabetes and treatment with the antioxidant alpha-lipoic acid on endothelial and neurogenic responses of corpus cavernosum in rats. Diabetologia (1999) 42 343-350.
5. Saenz de Tejada I., Goldstein I., Azadzoi K., Krane R.J., Cohen R.A. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med. (1989) 320 1025-1030.
6. Long T., Liu G., Wang Y., Chen Y., Zhang Y., Qin D. TNF-α, erectile dysfunction, and NADPH oxidase-mediated ROS generation in corpus cavernosum in high-fat diet/streptozotocin-induced diabetic rats. J. Sex Med. (2012) 9 1801-1814.
7. Li M., Zhuan L., Wang T. et al. Apocynin improves erectile function in diabetic rats through regulation of NADPH oxidase expression. J. Sex Med. (2012) 9 3041-3050.
8. Yang J., Wang T., Yang J. et al. S-allyl cysteine restores erectile function through inhibition of reactive oxygen species generation in diabetic rats. Andrology (2013) 1 487-494.
9. Bivalacqua T.J., Champion H.C., Usta M.F. et al. RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc. Natl Acad. Sci. USA (2004) 101 9121-9126.
10. Kendirci M., Tanriverdi O., Trost L., Hellstrom W.J. Management of sildenafil treatment failures. Curr. Opin. Urol. (2006) 16 449-459.
11. Malavige L.S., Levy J.C. Erectile dysfunction in diabetes mellitus. J. Sex Med. (2009) 6 1232-1247.
12. Huxtable R.J. Physiological action of taurine. Physiol. Rev. (1992) 72 101-163.
13. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem. J. (1988) 256 251-255.
14. Das J., Sil P.C. Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats. Amino Acids (2012) 43 1509-1523.
15. Wójcik O.P., Koenig K.L., Zeleniuch-Jacquotte A., Costa M., Chen Y. The potential protective effects of taurine on coronary heart disease. Atherosclerosis (2010) 208 19-25.
16. Yamori Y., Nara Y., Ikeda K., Mizushima S. Is taurine a preventive nutritional factor of cardiovascular diseases or just a biological marker of nutrition? Adv. Exp. Med. Biol. (1996) 403 623-629.
17. Moloney M.A., Casey R.G., O'Donnell D.H., Fitzgerald P., Thompson C., Bouchier-Hayes D.J. Two weeks taurine supplementation reverses endothelial dysfunction in young male type 1 diabetics. Diab. Vasc. Dis. Res. (2010) 7 300-310.
18. Ikubo N., Saito M., Tsounapi P. et al. Protective effect of taurine on diabetic rat endothelial dysfunction. Biomed. Res. (2011) 32 187-193.
19. Wang L.J., Yu Y.H., Zhang L.G. et al. Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: correlated with downregulation of LOX-1 and ICAM-1 expression on aortas. Eur. J. Pharmacol. (2008) 597 75-80.
20. Zulli A. Taurine in cardiovascular disease. Curr. Opin. Clin. Nutr. Metab. Care (2011) 14 57-60.
21. Yamori Y., Taguchi T., Hamada A., Kunimasa K., Mori H., Mori M. Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. J. Biomed. Sci. (2010) 17 S6.
22. Franconi F., Bennardini F., Mattana A. et al. Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am. J. Clin. Nutr. (1995) 61 1115-1119.
23. Franconi F., Miceli M., Fazzini A. et al. Taurine and diabetes. Humans and experimental models. Adv. Exp. Med. Biol. (1996) 403 579-582.
24. Abebe W., Mozaffari M.S. Effect of chronic taurine treatment on reactivity of rat aorta. Amino Acids (2000) 19 615-623.
25. Nicolosi A., Glasser D.B., Kim S.C., Marumo K., Laumann E.O. for the GSSAB Investigators' Group. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries. BJU Int. (2005) 95 609-614.
26. McCulloch D.K., Campbell I.W., Wu F.C., Prescott R.J., Clarke B.F. The prevalence of diabetic impotence. Diabetologia (1980) 18 279-283.
27. Lewis R.W., Fugl-Meyer K.S., Corona G. et al. Definitions/epidemiology/risk factors for sexual dysfunction. J. Sex Med. (2010) 4 1598-1607.
28. Zhang J., Li A.M., Liu B.X. et al. Effect of icarisid II on diabetic rats with erectile dysfunction and its potential mechanism via assessment of AGEs, autophagy, mTOR and the NO-cGMP pathway. Asian J. Androl. (2013) 15 143-148.
29. Yang G., Pan C., Lu J. Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. Int. J. Impot. Res. (2010) 22 310-317.
30. Fleming I., Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2003) 284 R1-R12.
31. Fulton D., Gratton J.P., McCabe T.J. et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature (1999) 399 597-601.
32. Fulton D., Gratton J.P., Sessa W.C. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/ calmodulin enough? J. Pharmacol. Exp. Ther. (2001) 299 818-824.
33. Somlyo A.P., Somlyo A.V. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. (2003) 83 1325.
34. Chang S., Hypolite J.A., Changolkar A., Wein A.J., Chacko S., DiSanto M.E. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int. J. Impot. Res. (2003) 15 53-62.
35. Ming X.F., Viswambharan H., Barandier C. et al. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol. Cell. Biol. (2002) 22 8467-8477.
36. Gao B.H., Zhao S.T., Meng F.W., Shi B.K., Liu Y.Q., Xu Z.S. Y-27632 improves the erectile dysfunction with ageing in SD rats through adjusting the imbalance between nNO and the Rho-kinase pathways. Andrologia (2007) 39 146-150.
37. Büyükafşar K., Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur. J. Pharmacol. (2003) 472 235-238.
38. Guzik T.J., West N.E., Black E. et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. (2000) 86 E85-E90.
39. Ebrahimian T.G., Heymes C., You D. et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am. J. Pathol. (2006) 169 719-728.
40. Zhang H., Zhang J., Ungvari Z., Zhang C. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler. Thromb. Vasc. Biol. (2009) 29 1164-1171.
41. Hink U., Li H., Mollnau H. et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. (2001) 88 E14-E22.
42. De Luca G., Calpona P.R., Caponetti A. et al. Taurine and osmoregulation: platelet taurine content, uptake, and release in type 2 diabetic patients. Metabolism (2001) 50 60-64.
43. Pop-Busui R., Sullivan K.A., Van Huysen C. et al. Depletion of taurine in experimental diabetic neuropathy: implications for nerve metabolic, vascular, and functional deficits. Exp. Neurol. (2001) 168 259-272.
44. Winiarska K., Szymanski K., Gorniak P., Dudziak M., Bryla J. Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie (2009) 91 261-270.
45. Angulo J., González-Corrochano R., Cuevas P. et al. Diabetes exacerbates the functional deficiency of NO/cGMP pathway associated with erectile dysfunction in human corpus cavernosum and penile arteries. J. Sex Med. (2010) 7 758-768.
46. Colivicchi M.A., Raimondi L., Bianchi L., Tipton K.F., Pirisino R., Della Corte L. Taurine prevents streptozotocin impairment of hormone-stimulated glucose uptake in rat adipocytes. Eur. J. Pharmacol. (2004) 495 209-215.
47. Li F., Obrosova I.G., Abatan O. et al. Taurine replacement attenuates hyperalgesia and abnormal calcium signaling in sensory neurons of STZ-D rats. Am. J. Physiol. Endocrinol. Metab. (2005) 288 E29-E36.
48. Li F., Abatan O.I., Kim H. et al. Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiol. Dis. (2006) 22 669-676.